Login to Your Account



Macrogenics draws Takeda to potential $500M alliance

By Marie Powers
Staff Writer

Tuesday, May 27, 2014
Macrogenics Inc. enticed another big pharma partner to the table with a candidate from its Dual-Affinity Re-Targeting, or DART platform. Takeda Pharmaceutical Co. Ltd., of Osaka, Japan, took an option to develop and commercialize MGD010, a preclinical asset targeting autoimmune diseases, that uses DART to simultaneously engage the B-cell surface proteins CD32B and CD79B.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription